Guardant Health, Inc.GHEarnings & Financial Report
Guardant Health, Inc. is an American biotechnology company based in Palo Alto, California. Co-founders Helmy Eltoukhy and AmirAli Talasaz serve as co-chief executive officers.
GH Q3 2025 Key Financial Metrics
Revenue
$265.2M
Gross Profit
$171.6M
Operating Profit
$-99.0M
Net Profit
$-92.7M
Gross Margin
64.7%
Operating Margin
-37.3%
Net Margin
-35.0%
YoY Growth
38.5%
EPS
$-0.74
Financial Flow
Guardant Health, Inc. Q3 2025 Financial Summary
Guardant Health, Inc. reported revenue of $265.2M for Q3 2025, with a net profit of $-92.7M (-35.0% margin). Cost of goods sold was $93.6M, operating expenses totaled $270.6M.
Key Financial Metrics
| Total Revenue | $265.2M |
|---|---|
| Net Profit | $-92.7M |
| Gross Margin | 64.7% |
| Operating Margin | -37.3% |
| Report Period | Q3 2025 |
Guardant Health, Inc. Annual Revenue by Year
Guardant Health, Inc. annual revenue history includes year-by-year totals (for example, 2024 revenue was $739.0M).
| Year | Annual Revenue |
|---|---|
| 2024 | $739.0M |
| 2023 | $563.9M |
| 2022 | $449.5M |
Income Statement
| Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $155.1M | $168.5M | $177.2M | $191.5M | $201.8M | $203.5M | $232.1M | $265.2M |
| YoY Growth | 22.2% | 30.9% | 29.2% | 33.9% | 30.2% | 20.8% | 30.9% | 38.5% |
Balance Sheet
| Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $1.79B | $1.70B | $1.61B | $1.54B | $1.49B | $1.34B | $1.33B | $1.28B |
| Liabilities | $1.63B | $1.64B | $1.61B | $1.60B | $1.63B | $1.60B | $1.64B | $1.63B |
| Equity | $158.7M | $68.3M | $-1.6M | $-60.1M | $-139.6M | $-250.8M | $-305.5M | $-354.5M |
Cash Flow
| Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $-78.7M | $-30.3M | $-94.0M | $-51.1M | $-64.5M | $-62.7M | $-60.3M | $-35.4M |
More Companies
ILMN
ILLUMINA, INC.
Revenue
$1.2B
Net Profit
$334.0M
UTHR
UNITED THERAPEUTICS Corp
Revenue
$799.5M
Net Profit
$338.7M
GMAB
GENMAB A/S
Revenue
$925.0M
Net Profit
$336.0M
NBIX
NEUROCRINE BIOSCIENCES INC
Revenue
$805.5M
Net Profit
$153.7M
EXEL
EXELIXIS, INC.
Revenue
$598.7M
Net Profit
$244.5M
MDGL
MADRIGAL PHARMACEUTICALS, INC.
Revenue
$287.3M
Net Profit
$-114.2M
QGEN
QIAGEN N.V.
BMRN
BIOMARIN PHARMACEUTICAL INC
Revenue
$776.1M
Net Profit
$-30.7M
ARWR
ARROWHEAD PHARMACEUTICALS, INC.
Revenue
$264.0M
Net Profit
$30.8M
BIO
BIO-RAD LABORATORIES, INC.
Revenue
$693.2M
Net Profit
$720.0M